Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: A population-based study

Firas Abdollah, Maxine Sun, Jan Schmitges, Rodolphe Thuret, Zhe Tian, Shahrokh F. Shariat, Alberto Briganti, Claudio Jeldres, Paul Perrotte, Francesco Montorsi, Pierre I. Karakiewicz

Research output: Contribution to journalArticle

Abstract

Purpose: Contemporary patients with localized prostate cancer (PCa) are more frequently treated with radiotherapy. However, there are limited data on the effect of this treatment on cancer-specific mortality (CSM). Our objective was to test the relationship between radiotherapy and survival in men with localized PCa and compare it with those treated with observation. Methods: A population-based cohort identified 68,797 men with cT1-T2 PCa treated with radiotherapy or observation between the years 1992 and 2005. Propensity-score matching was used to minimize potential bias related to treatment assignment. Competing-risks analyses tested the effect of treatment type (radiotherapy vs. observation) on CSM, after accounting to other-cause mortality. All analyses were carried out within PCa risk, baseline comorbidity status, and age groups. Results: Radiotherapy was associated with more favorable 10-year CSM rates than observation in patients with high-risk PCa (8.8 vs. 14.4%, hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.50-0.68). Conversely, the beneficial effect of radiotherapy on CSM was not evident in patients with low-intermediate risk PCa (3.7 vs. 4.1%, HR: 0.91, 95% CI: 0.80-1.04). Radiotherapy was beneficial in elderly patients (5.6 vs. 7.3%, HR: 0.70, 95% CI: 0.59-0.80). Moreover, it was associated with improved CSM rates among patients with no comorbidities (5.7 vs. 6.5%, HR: 0.81, 95% CI: 0.67-0.98), one comorbidity (4.6 vs. 6.0%, HR: 0.87, 95% CI: 0.75-0.99), and more than two comorbidities (4.2 vs. 5.0%, HR: 0.79, 95% CI: 0.65-0.96). Conclusions: Radiotherapy substantially improves CSM in patients with high-risk PCa, with little or no benefit in patients with low-/intermediate-risk PCa relative to observation. These findings must be interpreted within the context of the limitations of observational data.

Original languageEnglish
Pages (from-to)95-103
Number of pages9
JournalInternational Journal of Radiation Oncology Biology Physics
Volume84
Issue number1
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

mortality
radiation therapy
Prostatic Neoplasms
Radiotherapy
cancer
Observation
Mortality
Confidence Intervals
Population
Comorbidity
hazards
confidence
Neoplasms
intervals
Propensity Score
Therapeutics
Age Groups
Survival

Keywords

  • Observation
  • Prostatic neoplasms/mortality
  • Prostatic neoplasms/therapy
  • Radiotherapy/statistics and numerical data
  • SEER program

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Radiation
  • Cancer Research

Cite this

Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer : A population-based study. / Abdollah, Firas; Sun, Maxine; Schmitges, Jan; Thuret, Rodolphe; Tian, Zhe; Shariat, Shahrokh F.; Briganti, Alberto; Jeldres, Claudio; Perrotte, Paul; Montorsi, Francesco; Karakiewicz, Pierre I.

In: International Journal of Radiation Oncology Biology Physics, Vol. 84, No. 1, 01.09.2012, p. 95-103.

Research output: Contribution to journalArticle

Abdollah, Firas ; Sun, Maxine ; Schmitges, Jan ; Thuret, Rodolphe ; Tian, Zhe ; Shariat, Shahrokh F. ; Briganti, Alberto ; Jeldres, Claudio ; Perrotte, Paul ; Montorsi, Francesco ; Karakiewicz, Pierre I. / Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer : A population-based study. In: International Journal of Radiation Oncology Biology Physics. 2012 ; Vol. 84, No. 1. pp. 95-103.
@article{2e35d9e25ef348cbb5dae345afbd5169,
title = "Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: A population-based study",
abstract = "Purpose: Contemporary patients with localized prostate cancer (PCa) are more frequently treated with radiotherapy. However, there are limited data on the effect of this treatment on cancer-specific mortality (CSM). Our objective was to test the relationship between radiotherapy and survival in men with localized PCa and compare it with those treated with observation. Methods: A population-based cohort identified 68,797 men with cT1-T2 PCa treated with radiotherapy or observation between the years 1992 and 2005. Propensity-score matching was used to minimize potential bias related to treatment assignment. Competing-risks analyses tested the effect of treatment type (radiotherapy vs. observation) on CSM, after accounting to other-cause mortality. All analyses were carried out within PCa risk, baseline comorbidity status, and age groups. Results: Radiotherapy was associated with more favorable 10-year CSM rates than observation in patients with high-risk PCa (8.8 vs. 14.4{\%}, hazard ratio [HR]: 0.59, 95{\%} confidence interval [CI]: 0.50-0.68). Conversely, the beneficial effect of radiotherapy on CSM was not evident in patients with low-intermediate risk PCa (3.7 vs. 4.1{\%}, HR: 0.91, 95{\%} CI: 0.80-1.04). Radiotherapy was beneficial in elderly patients (5.6 vs. 7.3{\%}, HR: 0.70, 95{\%} CI: 0.59-0.80). Moreover, it was associated with improved CSM rates among patients with no comorbidities (5.7 vs. 6.5{\%}, HR: 0.81, 95{\%} CI: 0.67-0.98), one comorbidity (4.6 vs. 6.0{\%}, HR: 0.87, 95{\%} CI: 0.75-0.99), and more than two comorbidities (4.2 vs. 5.0{\%}, HR: 0.79, 95{\%} CI: 0.65-0.96). Conclusions: Radiotherapy substantially improves CSM in patients with high-risk PCa, with little or no benefit in patients with low-/intermediate-risk PCa relative to observation. These findings must be interpreted within the context of the limitations of observational data.",
keywords = "Observation, Prostatic neoplasms/mortality, Prostatic neoplasms/therapy, Radiotherapy/statistics and numerical data, SEER program",
author = "Firas Abdollah and Maxine Sun and Jan Schmitges and Rodolphe Thuret and Zhe Tian and Shariat, {Shahrokh F.} and Alberto Briganti and Claudio Jeldres and Paul Perrotte and Francesco Montorsi and Karakiewicz, {Pierre I.}",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.ijrobp.2011.11.034",
language = "English",
volume = "84",
pages = "95--103",
journal = "International Journal of Radiation Oncology Biology Physics",
issn = "0360-3016",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer

T2 - A population-based study

AU - Abdollah, Firas

AU - Sun, Maxine

AU - Schmitges, Jan

AU - Thuret, Rodolphe

AU - Tian, Zhe

AU - Shariat, Shahrokh F.

AU - Briganti, Alberto

AU - Jeldres, Claudio

AU - Perrotte, Paul

AU - Montorsi, Francesco

AU - Karakiewicz, Pierre I.

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Purpose: Contemporary patients with localized prostate cancer (PCa) are more frequently treated with radiotherapy. However, there are limited data on the effect of this treatment on cancer-specific mortality (CSM). Our objective was to test the relationship between radiotherapy and survival in men with localized PCa and compare it with those treated with observation. Methods: A population-based cohort identified 68,797 men with cT1-T2 PCa treated with radiotherapy or observation between the years 1992 and 2005. Propensity-score matching was used to minimize potential bias related to treatment assignment. Competing-risks analyses tested the effect of treatment type (radiotherapy vs. observation) on CSM, after accounting to other-cause mortality. All analyses were carried out within PCa risk, baseline comorbidity status, and age groups. Results: Radiotherapy was associated with more favorable 10-year CSM rates than observation in patients with high-risk PCa (8.8 vs. 14.4%, hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.50-0.68). Conversely, the beneficial effect of radiotherapy on CSM was not evident in patients with low-intermediate risk PCa (3.7 vs. 4.1%, HR: 0.91, 95% CI: 0.80-1.04). Radiotherapy was beneficial in elderly patients (5.6 vs. 7.3%, HR: 0.70, 95% CI: 0.59-0.80). Moreover, it was associated with improved CSM rates among patients with no comorbidities (5.7 vs. 6.5%, HR: 0.81, 95% CI: 0.67-0.98), one comorbidity (4.6 vs. 6.0%, HR: 0.87, 95% CI: 0.75-0.99), and more than two comorbidities (4.2 vs. 5.0%, HR: 0.79, 95% CI: 0.65-0.96). Conclusions: Radiotherapy substantially improves CSM in patients with high-risk PCa, with little or no benefit in patients with low-/intermediate-risk PCa relative to observation. These findings must be interpreted within the context of the limitations of observational data.

AB - Purpose: Contemporary patients with localized prostate cancer (PCa) are more frequently treated with radiotherapy. However, there are limited data on the effect of this treatment on cancer-specific mortality (CSM). Our objective was to test the relationship between radiotherapy and survival in men with localized PCa and compare it with those treated with observation. Methods: A population-based cohort identified 68,797 men with cT1-T2 PCa treated with radiotherapy or observation between the years 1992 and 2005. Propensity-score matching was used to minimize potential bias related to treatment assignment. Competing-risks analyses tested the effect of treatment type (radiotherapy vs. observation) on CSM, after accounting to other-cause mortality. All analyses were carried out within PCa risk, baseline comorbidity status, and age groups. Results: Radiotherapy was associated with more favorable 10-year CSM rates than observation in patients with high-risk PCa (8.8 vs. 14.4%, hazard ratio [HR]: 0.59, 95% confidence interval [CI]: 0.50-0.68). Conversely, the beneficial effect of radiotherapy on CSM was not evident in patients with low-intermediate risk PCa (3.7 vs. 4.1%, HR: 0.91, 95% CI: 0.80-1.04). Radiotherapy was beneficial in elderly patients (5.6 vs. 7.3%, HR: 0.70, 95% CI: 0.59-0.80). Moreover, it was associated with improved CSM rates among patients with no comorbidities (5.7 vs. 6.5%, HR: 0.81, 95% CI: 0.67-0.98), one comorbidity (4.6 vs. 6.0%, HR: 0.87, 95% CI: 0.75-0.99), and more than two comorbidities (4.2 vs. 5.0%, HR: 0.79, 95% CI: 0.65-0.96). Conclusions: Radiotherapy substantially improves CSM in patients with high-risk PCa, with little or no benefit in patients with low-/intermediate-risk PCa relative to observation. These findings must be interpreted within the context of the limitations of observational data.

KW - Observation

KW - Prostatic neoplasms/mortality

KW - Prostatic neoplasms/therapy

KW - Radiotherapy/statistics and numerical data

KW - SEER program

UR - http://www.scopus.com/inward/record.url?scp=84865679741&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84865679741&partnerID=8YFLogxK

U2 - 10.1016/j.ijrobp.2011.11.034

DO - 10.1016/j.ijrobp.2011.11.034

M3 - Article

C2 - 22330991

AN - SCOPUS:84865679741

VL - 84

SP - 95

EP - 103

JO - International Journal of Radiation Oncology Biology Physics

JF - International Journal of Radiation Oncology Biology Physics

SN - 0360-3016

IS - 1

ER -